| Trial ID: | L1564 |
| Source ID: | NCT06664125
|
| Associated Drug: |
Jmkx003002 Will Be Administered Orally
|
| Title: |
Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Hyperphosphatemia
|
| Interventions: |
DRUG: JMKX003002 will be administered orally|DRUG: Sevelamer carbonate
|
| Outcome Measures: |
Primary: To preliminarily evaluate the efficacy of JMKX003002 in decreasing serum phosphorus of ESRD patients on hemodialysis, The change in serum phosphorus (sP) level from baseline to the end of treatment, 4 weeks |
|
| Sponsor/Collaborators: |
Sponsor: Jemincare
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
50
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2024-12-30
|
| Completion Date: |
2025-09-30
|
| Results First Posted: |
|
| Last Update Posted: |
2025-02-03
|
| Locations: |
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
|
| URL: |
https://clinicaltrials.gov/show/NCT06664125
|
